ALS Therapy Nears Canadian Approval Filing in December

People living with ALS in Canada could soon have access to a new treatment option that clinical trials suggest may significantly slow the disease's devastating progression.

Neurosense Therapeutics announced it will submit PrimeC, an experimental oral therapy for amyotrophic lateral sclerosis, to Health Canada for approval by December 2026. The regulatory agency raised no concerns about the timeline and gave the company a clear path forward after a pre-submission meeting.

PrimeC combines two already-approved medications into an extended-release tablet taken twice daily. The therapy targets inflammation and other biological processes that damage the nerve cells controlling movement in ALS patients.

The treatment's promise comes from the Phase 2b PARADIGM trial, which enrolled 68 adults with ALS. Results showed PrimeC significantly reduced levels of TDP-43, a protein that abnormally builds up in nerve cells in nearly all ALS cases. Those reductions lasted throughout the 18-month study period.

Beyond biomarker improvements, the data revealed something even more encouraging. Participants who took PrimeC from the start maintained better physical function than those who initially received a placebo. After 18 months, their ability to perform daily tasks scored nearly 8 points higher on the standard ALS assessment scale.

The survival data offered the most hope. People who started PrimeC immediately had an estimated median survival of 36 months, compared to 21 months for those who began with placebo and switched later. That's nearly 15 additional months with loved ones.

Neurosense is pursuing Canada's conditional approval pathway, which allows earlier access to promising therapies for serious diseases with limited treatment options. Currently, available ALS treatments provide only modest benefits, leaving patients and families desperate for better options.

The Ripple Effect

If approved in Canada, PrimeC won't just help patients north of the border. The authorization could pave the way for faster approvals in other countries where people with ALS are waiting. Neurosense is already preparing PARAGON, a larger Phase 3 trial launching across the U.S. and Europe with 300 participants that could provide the evidence needed for broader approval.

ALS robs people of their ability to move, speak, swallow, and eventually breathe as nerve cells die. For patients facing this relentless disease, every month matters. The fact that PrimeC uses two medications already proven safe in other conditions could help speed its path to those who need it most.

December's filing represents more than a regulatory milestone for one company or one country. It's a tangible step toward giving people with ALS something they need desperately: time and hope.